Horizon PharmaHZNP was up 3.3% after the company announced encouraging expected net sales for the second quarter of 2015 and upped its 2015 guidance.
The company expects second quarter 2015 net sales in the range of $170 million to $172 million, up approximately 160% from the year-ago quarter and approximately 50% sequentially. The company also stated that the second quarter adjusted EBITDA margin is expected to improve significantly on a sequential basis.
The adjusted EBITDA number and additional data will be provided as part of the second quarter 2015 earnings release scheduled on Aug 7, 2015.
2015 Guidance Raised
Horizon Pharma raised its 2015 guidance based on strong performance through the second quarter of 2015.
The company now expects 2015 net sales to be around $660 million to $680 million as compared to the previous range of $590 million to $610 million. The Zacks Consensus Estimate is currently at $608 million. Horizon Pharma also raised its adjusted EBITDA guidance to the range of $265 million to $280 million from the previous range of $235 million to $250 million.
We are encouraged by the company's second quarter net sales guidance. We expect the top line to be driven by the inclusion of Actimmune revenues. The company's 2015 guidance also looks impressive.
Horizon Pharma carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector are Ligand Pharmaceuticals Incorporated LGND , AMAG Pharmaceuticals, Inc. AMAG and Anacor Pharmaceuticals, Inc. ANAC . While Ligand and AMAG carry a Zacks Rank #1 (Strong Buy), Anacor holds a Zacks Rank #2 (Buy).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.